Wockhardt Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Wockhardt Ltd. from all sources in a single place.

Load latest

Wockhardt Ltd.

02 Jan 2025

1834.40

0.74%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of the Listing Regulations, please find attached Press Release titled- Indian Drug Regulator Approves Wockhardt''s New Generation Oral Antibiotic MiqnafR (Nafithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP).

pdf

Wockhardt Ltd.

26 Dec 2024

1834.40

0.74%

SAST

WOCKHARDT LTD. - 532300 - Closure of Trading Window

BSE India

This is to inform you that pursuant to Company''s Code of Conduct for regulating, monitoring and reporting trading by Designated persons, the trading window for dealing in the equity shares of the Company will be closed from 1st January, 2025 until 48 hours after the declaration of unaudited financial results for quarter and nine months ended on 31st December, 2024.

pdf

Wockhardt Ltd.

24 Dec 2024

1834.40

0.74%

Murmu, VP Dhankhar, and LS Speaker Birla condole Shyam Benegal's demise

Business Standard

Benegal, a pivotal figure in Indian cinema, passed away on Monday at the age of 90 at Wockhardt Hospital, Mumbai Central

Wockhardt Ltd. has gained 31.74% in the last 3 Months

Shyam Benegal no more: Look back at illustrious work of veteran filmmaker

Business Standard | 23 Dec 2024 1 more

Wockhardt Ltd.

16 Dec 2024, 07:54PM

1834.40

0.74%

Wockhardt's Zaynich gives new hope to cancer patient with successful liver transplant

Business Line

The drug effectively cleared a chronic bile duct infection, enabling the patient to undergo a liver transplant and resume chemotherapy.

Wockhardt Ltd. has an average target of 1870.00 from 1 broker.

Wockhardt Share Price At Life High As Patent Drug Aids US Patient With Transplant Surgery

NDTV Profit | 16 Dec 2024, 12:37PM 1 more

Wockhardt Ltd.

16 Dec 2024, 08:58AM

1834.40

0.74%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find attached Press Release titled, "Zaynich TM (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotheraphy by eradicating dual extreme-drug resistant Gram negative pathogens"

pdf

Wockhardt Ltd.

06 Dec 2024

1834.40

0.74%

Indigenous development of Nafithromycin marks key milestone in AMR battle: Government

Business Line

Developed by Wockhardt, it is a first in its class to be introduced globally in over 30 years

Wockhardt Ltd. has an average target of 1870.00 from 1 broker.

Wockhardt Ltd.

05 Dec 2024

1834.40

0.74%

Indian pharma develops more effective drug to combat antibiotic-resistance

Business Standard

Wockhardt's nafithromycin is India's first FDA-approved antimicrobial that is seen as an alternative to existing antibiotics like azithromycin, which is facing increasing resistance in humans

Axis Direct released a Buy report for Wockhardt Ltd. with a price target of 1870.0 on 08 Jul, 2025.

Wockhardt Ltd.

27 Nov 2024

1834.40

0.74%

Corp. Note

WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate …

BSE India

Pursuant to the requirement of the Regulation 39(3) of the SEBI Listing Regulations, we wish to inform you that our RTA has intimated about receipt of the request for the issuance of Duplicate Share Certificate in lieu of the Original Certificate lost/misplaced.

pdf

Wockhardt Ltd.

22 Nov 2024

1834.40

0.74%

Rs 8 Crore Assistance': Govt Fact Checks Claims On Nafithromycin Antibiotic

NDTV Profit

The Department of Biotechnology clarified that Wockhardt invested Rs 500 crore in developing Nafithromycin, with Rs 8 crore financial support from BIRAC for trials.

Wockhardt Ltd. has an average target of 1870.00 from 1 broker.

Wockhardt Ltd.

21 Nov 2024

1834.40

0.74%

Corp. Note

WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate …

BSE India

Pursuant to the requirement of the Regulation 39(3) of the SEBI Listing Regulations, we wish to inform the Stock Exchange that our RTA has intimated about receipt of the Duplicate Share Certificates in lieu of the original Share Certificate reported lost/misplaced.

pdf

Is Wockhardt Ltd. worth buying?

448 Votes:

Buy 73.44%

Sell 17.19%

Hold 9.38%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Results Update SEE REPORTS >

pdf

Near 52W High of ₹1868.80

Wockhardt Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Wockhardt Ltd. from all sources in a single place.